دورية أكاديمية
أعرض في EDS

LncRNA JHDM1D-AS1 Is a Key Biomarker for Progression and Modulation of Gemcitabine Sensitivity in Bladder Cancer Cells.

التفاصيل البيبلوغرافية
العنوان: LncRNA JHDM1D-AS1 Is a Key Biomarker for Progression and Modulation of Gemcitabine Sensitivity in Bladder Cancer Cells.
المؤلفون: Pereira IOA; Departamento de Análises Clínicas, Pharmacy School, UFOP-Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil., da Silva GN; Departamento de Análises Clínicas, Pharmacy School, UFOP-Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil., Almeida TC; Laboratory of Pain and Signaling, Butantan Institute, Sao Paulo 05503-900, SP, Brazil., Lima APB; Departamento de Análises Clínicas, Pharmacy School, UFOP-Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil., Sávio ALV; Departamento de Odontologia, Faculdade do Centro Oeste Paulista-FACOP, Piratininga 17490-000, SP, Brazil.; Departamento de Ciências Médicas, Universidade do Oeste Paulista-UNOESTE, Jaú 19050-900, SP, Brazil., Leite KRM; Departamento de Cirurgia, Medical School, USP-University of São Paulo, São Paulo 05508-060, SP, Brazil., Salvadori DMF; Departamento de Patologia, Medical School, UNESP-São Paulo State University, Botucatu 01151-000, SP, Brazil.
المصدر: Molecules (Basel, Switzerland) [Molecules] 2023 Mar 06; Vol. 28 (5). Date of Electronic Publication: 2023 Mar 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c1995-
مواضيع طبية MeSH: RNA, Long Noncoding*/genetics , Urinary Bladder Neoplasms*/pathology, Humans ; Gemcitabine ; Urinary Bladder/metabolism ; Cell Line, Tumor ; Biomarkers ; Cell Movement/genetics ; Cell Proliferation/genetics ; Gene Expression Regulation, Neoplastic
مستخلص: Long non-coding RNAs are frequently found to be dysregulated and are linked to carcinogenesis, aggressiveness, and chemoresistance in a variety of tumors. As expression levels of the JHDM1D gene and lncRNA JHDM1D-AS1 are altered in bladder tumors, we sought to use their combined expression to distinguish between low-and high-grade bladder tumors by RTq-PCR. In addition, we evaluated the functional role of JHDM1D-AS1 and its association with the modulation of gemcitabine sensitivity in high-grade bladder-tumor cells. J82 and UM-UC-3 cells were treated with siRNA- JHDM1D-AS1 and/or three concentrations of gemcitabine (0.39, 0.78, and 1.56 µM), and then submitted to cytotoxicity testing (XTT), clonogenic survival, cell cycle progression, cell morphology, and cell migration assays. When JHDM1D and JHDM1D-AS1 expression levels were used in combination, our findings indicated favorable prognostic value. Furthermore, the combined treatment resulted in greater cytotoxicity, a decrease in clone formation, G0/G1 cell cycle arrest, morphological alterations, and a reduction in cell migration capacity in both lineages compared to the treatments alone. Thus, silencing of JHDM1D-AS1 reduced the growth and proliferation of high-grade bladder-tumor cells and increased their sensitivity to gemcitabine treatment. In addition, the expression of JHDM1D/JHDM1D-AS1 indicated potential prognostic value in the progression of bladder tumors.
References: Cancer Invest. 2023 Feb;41(2):164-172. (PMID: 36373675)
Br J Cancer. 1995 Sep;72(3):683-90. (PMID: 7669581)
J Clin Lab Anal. 2021 Jun;35(6):e23797. (PMID: 33960436)
Oncotarget. 2014 Sep 30;5(18):8027-38. (PMID: 25275300)
Int J Biochem Cell Biol. 2013 Aug;45(8):1895-910. (PMID: 23748105)
Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20725-9. (PMID: 22143793)
Adv Exp Med Biol. 2017;1008:1-46. (PMID: 28815535)
Mutagenesis. 2020 Aug 13;:. (PMID: 32789469)
Mol Cell Biol. 2017 Aug 28;37(18):. (PMID: 28652266)
Cancer Res. 2004 Aug 1;64(15):5245-50. (PMID: 15289330)
Turk J Emerg Med. 2018 Aug 07;18(3):91-93. (PMID: 30191186)
Biomed Pharmacother. 2018 Jul;103:415-420. (PMID: 29674277)
Mol Biosyst. 2012 Sep;8(9):2289-94. (PMID: 22722759)
Int J Mol Sci. 2020 Aug 06;21(16):. (PMID: 32781788)
J Urol. 2016 Oct;196(4):1021-9. (PMID: 27317986)
Med Sci (Basel). 2020 Mar 13;8(1):. (PMID: 32183076)
BMC Genomics. 2015 May 22;16:403. (PMID: 25997541)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Clin Genitourin Cancer. 2017 Oct;15(5):570-576. (PMID: 28648755)
RNA Biol. 2012 Jun;9(6):703-19. (PMID: 22664915)
Acta Biochim Biophys Sin (Shanghai). 2019 Nov 18;51(11):1148-1157. (PMID: 31650173)
Mol Ther Nucleic Acids. 2019 Dec 6;18:831-840. (PMID: 31739208)
Life Sci. 2021 Jan 15;265:118805. (PMID: 33245963)
FEBS J. 2014 Apr;281(7):1750-8. (PMID: 24495014)
Environ Mol Mutagen. 2019 Oct;60(8):740-751. (PMID: 31095781)
FEBS Lett. 2008 Jun 11;582(13):1919-27. (PMID: 18501714)
J Cancer Res Ther. 2018 Oct-Dec;14(6):1260-1265. (PMID: 30488841)
Nat Rev Urol. 2019 Aug;16(8):484-504. (PMID: 31110275)
Int J Cancer. 2016 Jul 15;139(2):269-80. (PMID: 26875870)
Oncol Lett. 2017 Nov;14(5):5556-5562. (PMID: 29113184)
Cancer Lett. 2017 Oct 28;407:106-112. (PMID: 28400335)
Nat Rev Urol. 2017 Sep;14(9):565-574. (PMID: 28675174)
J Cell Mol Med. 2019 Mar;23(3):2149-2162. (PMID: 30614617)
Methods Mol Med. 2005;110:21-8. (PMID: 15901923)
Cancer Lett. 2016 Nov 1;382(1):64-76. (PMID: 27591936)
Exp Biol Med (Maywood). 2010 Jul;235(7):814-24. (PMID: 20558835)
Oncotarget. 2018 Jun 19;9(47):28514-28531. (PMID: 29983877)
J Lab Autom. 2012 Feb;17(1):59-65. (PMID: 22357609)
Int J Cancer. 2018 Dec 1;143(11):2849-2861. (PMID: 30183076)
Mol Biol Rep. 2012 Dec;39(12):10373-82. (PMID: 23053941)
J Cell Physiol. 2020 Feb;235(2):932-943. (PMID: 31236965)
Oncotarget. 2016 Feb 23;7(8):8663-75. (PMID: 26848616)
BMC Cancer. 2013 Dec 21;13:604. (PMID: 24359526)
Cancer Res. 2015 Sep 15;75(18):3728-37. (PMID: 26208906)
Expert Rev Anticancer Ther. 2016;16(3):255-71. (PMID: 26781169)
Nat Rev Dis Primers. 2017 Apr 13;3:17022. (PMID: 28406148)
معلومات مُعتمدة: 310905/2020-6 National Council for Scientific and Technological Development; 307201/2021-0 National Council for Scientific and Technological Development; Finance Code 001 Coordenação de Aperfeicoamento de Pessoal de Nível Superior; PROPPI/UFOP Nº 03/2023 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; PROPPI/UFOP Nº 03/2023 Universidade Federal de Ouro Preto
فهرسة مساهمة: Keywords: JHDM1D-AS1; bladder cancer; long non-coding RNAs
المشرفين على المادة: 0 (RNA, Long Noncoding)
0 (Gemcitabine)
0 (Biomarkers)
تواريخ الأحداث: Date Created: 20230311 Date Completed: 20230314 Latest Revision: 20230314
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10005151
DOI: 10.3390/molecules28052412
PMID: 36903656
قاعدة البيانات: MEDLINE
الوصف
تدمد:1420-3049
DOI:10.3390/molecules28052412